AU ZH, Switzerland, June 13, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the...
AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (Araris or the Company), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced...
Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates
AU ZH, Switzerland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (œAraris), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they...
ZURICH, SWITZERLAND, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (œAraris), a company developing ADCs using its proprietary linker-payload technology, today announced the appointment of...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that, Innosuisse, the Swiss innovation agency committed to promote science-based innovation in the interest of the economy and society in Switzerland, has supported Araris with CHF 2.5M non-dilutive grant funding through the Swiss Accelerator program for the development and advancement of its ADC candidates.
Innosuisse supports 53 companies out of 752 applications with total CHF 112MAraris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC)...
Araris Biotech AG Acquires ARS Pharmaceutical’s Nectin-4 Antibody
Araris Biotech AG Presents Preclinical Data Highlighting Stable and Efficacious Low Drug-Load ADCs at American Association for Cancer Research (AACR) Annual Meeting 2023
Araris Biotech AG Announces Strategic Investment with Samsung Ventures